# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹380 Cr** Q2 FY'26 (+5%) · **₹732 Cr** H1 FY'26 (+5%) * Consolidated Revenue: ₹380.4 Cr Q2 FY'26 (+19.5%) · ₹731.9 Cr H1 FY'26 * EBITDA: ₹112.6 Cr H1 FY'26 (+17%) · ₹56.1 Cr Q3 FY'26 (+8% YoY) * **EBITDA Margin:** ~**15%** · **PAT Margin:** ~**8%** ## B. Revenue Growth * **Resilient Top-Line Performance:** Revenue growth held firm at 5% YoY despite pricing pressure in CDMO segment, underpinned by healthy volume expansion and growing market share. * **Group-Level Momentum:** Strong customer demand and broadening footprint driving volume gains across the business, signaling durable underlying growth trends. ## C. EBITDA & Margins * **Margin Resilience & Efficiency Gains:** EBITDA growth outpaced revenue, reflecting operational improvements and stabilization in API prices despite margin headwinds. * **Sustainable Margin Target:** B2B segment targets **13–17% EBITDA margins** with a **15% median**, expected to be achieved at Jammu facility upon reaching stable production scale. ## D. Cash Flow Trends * **Working Capital Expansion for Growth:** Increase in receivables, inventory, and **12-day rise in working capital days** reflects strategic buildup to support near-term sales ramp. * **Near-Term Normalization Expected:** Management anticipates working capital cycle to revert toward **85–90 days** as revenue scales, supporting future cash flow conversion. --- # 2. Segment & Product Performance ## A. Key Figures * CDMO Revenue: ₹265.7 Cr Q2 FY'26 (+15%) · ₹515.2 Cr H1 FY'26 * **Branded Generics Revenue:** ₹7 Cr H1 FY'26 (+43%) · Q2 FY'26 up **31% YoY** ## B. CDMO Business * **Operational Momentum:** CDMO growth driven by **Jammu facility ramp-up** and strong client engagement, with operations live and advanced discussions ongoing. * **Volume-Price Trade-off:** Baddi facilities delivered **8–10% volume growth** despite **10–12% domestic price erosion**, highlighting competitive intensity and volume-led strategy. * **Segment Reclassification:** Business now split into CDMO and Branded Generics; prior-period segment data not comparable due to reclassification. ## C. Branded Generics * **Accelerated Expansion:** Branded Generics shows **strong double-digit growth**, fueled by broader product portfolio and intensified marketing execution. ## D. Sharon Bio Contribution * **Strategic Fit Confirmed:** Sharon Bio acquisition performing in line with group growth, contributing steadily to top line with no drag. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Jammu Sales (H1):** **₹120 Cr** (actual) · **₹240–250 Cr** (FY guidance) * **Jammu Investment:** **₹480+ Cr** (total) * **Jammu Revenue Potential:** **>₹1,400 Cr** (at 65–70% utilization) · **>₹1,000 Cr** (target in 3 years) ## B. Jammu Facility Ramp-up * **Resilient Ramp-up:** Jammu facility achieving strong revenue momentum despite **15–20% API price correction**, including potassium clavulanate falling to **₹13,000/kg**. * **Margin Progress:** Plant is nearing EBITDA breakeven on current turnover, with **GST reduction from 12% to 5%** positively impacting cost structure; updated EBITDA trajectory to be shared in coming quarters. * **Capacity & Growth Trajectory:** Full ramp-up expected over 3–4 years, with 65–70% utilization seen as optimal, supporting the company’s **20%+ long-term revenue growth** target. * **Investment Clarity:** Management confirmed actual Jammu investment is **₹480 Cr**, not ₹700 Cr, correcting market misperceptions around asset turnover and revenue potential. --- # 4. Geography & Export Mix ## A. Key Figures * **Export Contribution:** **30%** of revenue (Q2 FY'26) · **30%** of revenue (H1 FY'26) ## B. Export Contribution * **Stable International Exposure:** Exports maintained consistent contribution to revenue, reflecting a well-diversified geographical mix. --- # 5. Regulatory & Compliance ## A. Key Figures * **GST Rate:** **5%** for Pharmaceutical Formulations (from 12%) impacting Jammu unit incentives * **Interest Subvention Benefit:** **6%** on term loans for plant & machinery at Jammu facility ## B. GST Impact * **Reduced Tax Burden:** Lower GST rate of 5% enhances cost competitiveness for formulations, though it recalibrates incentive economics at the Jammu manufacturing unit. * **Financing Support:** Jammu unit retains strong financial support via **6% interest subvention**, partially offsetting incentive adjustments. ## C. cGMP Standards * **Global Compliance Validation:** Successful UK-MHRA and Ukraine SMDC inspections affirm adherence to international cGMP standards, bolstering export market access. * **Elevated Regulatory Scrutiny:** Increased oversight from CDSCO and global agencies includes **more frequent sampling** and **stricter Schedule M enforcement**, driven by recent safety incidents. * **Proactive Stance:** Management prioritizes forward-looking compliance to navigate tightening regulations, emphasizing long-term operational resilience. --- # 6. Risks & Regulatory Pressures ## A. Key Figures * **Reimbursement Rate:** **5%** post-reduction (from 12%) * **GST Incentive Cap:** **₹75–80 Cr** in Jammu (unchanged) * **Revenue Threshold for Incentive:** **₹1,400 Cr** required annually (up from ₹650 Cr) ## B. Margin Pressure * **Partial Margin Protection:** Company will **not fully absorb the 7% reimbursement cut**, retaining a portion of the margin through selective client pricing. * **Offsetting Competitive Edge:** Despite a **negative 7% margin impact from GST reduction**, the business maintains a **5% price advantage over peers**, supporting margin resilience. * **Long-Term Margin Target Intact:** Management affirms **15% margin sustainability** is achievable via B2B pricing flexibility despite short-term headwinds. ## C. Compliance Delays * **Extended Timelines:** Regulatory validation now taking **2x to 3x longer** due to stricter stability and batch requirements, increasing time-to-market. * **Compliance as Moat:** Early movers adapting to tighter norms are positioned to convert regulatory pressure into **long-term competitive advantage**. ## D. Incentive Capping * **Diluted Incentive Efficiency:** Fixed GST incentive cap now requires **over double the revenue** to reach maximum benefit, reducing incremental returns at scale. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target:** **INR 1,000–1,200 Cr** post-IPO run rate · **INR 400 Cr** annual target from new facility * **Long-Term Revenue Goal:** **>INR 1,000 Cr** from Jammu facility post-scaling * **Margin Outlook:** **15%** sustained long-term EBITDA margin expected ## B. Revenue Targets * **Strategic Scaling:** Commitment to **tripling scale** over next 3 years, targeting full doubling of top line, EBITDA, and PAT. * **Facility Focus:** New facility central to growth, with **INR 400 Cr** annual turnover objective guiding near-term investment. ## C. Breakeven Timeline * **Revised Ramp-Up:** Jammu facility tracking below initial expectations due to market headwinds, now projected at **INR 250 Cr**, though on a **clear professional trajectory**. ## D. Growth Trajectory * **Historical Momentum:** Proven **20%+ annual growth** trend over past cycles, with management guiding for sustained expansion post-IPO. * **GST Impact & Margin Path:** Short-term incentive headwinds from GST change; **long-term margin sustainability** expected at **15%** as efficiencies mature.